{"id":"W2806421431","doi":"10.1016/s1470-2045(18)30365-6","title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":409,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Oncology; Enzalutamide; PARP inhibitor; Placebo; Clinical endpoint; Docetaxel; Population; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001704627,0.002834331,0.004322777,0.0007609331,0.0005928594,0.001733421,0.001079273,0.002299151,0.007596233],"category_scores_gemma":[0.002689322,0.001126944,0.002262198,0.0006874701,0.001907216,0.001823976,0.0006236112,0.004013986,0.001528145],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007736041,"about_ca_system_score_gemma":0.001195144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001199792,"about_ca_topic_score_gemma":0.002185704,"domain_scores_codex":[0.9991189,0.0004564413,0.00006241995,0.0001731754,0.00006788763,0.0001212538],"domain_scores_gemma":[0.9989157,0.0003442929,0.0002256626,0.00009658277,0.00005710384,0.0003606038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9874094,0.0017569,0.0001601909,0.0006724754,0.000618156,0.00002569162,0.00003970986,0.0001904505,0.0009691683,0.00006173518,0.0003992681,0.007696804],"study_design_scores_gemma":[0.9797533,0.01896,0.000327811,0.00002545437,0.0002226549,0.00002186193,0.00001412083,0.0001430015,0.0001022838,0.000103393,0.0003143854,0.00001186593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9653956,0.01827027,0.001713232,0.001623457,0.00203176,0.004752944,0.002075156,0.0004471783,0.003690457],"genre_scores_gemma":[0.977715,0.008448423,0.001883077,0.001602818,0.001045187,0.003612786,0.001291077,0.00006005023,0.004341421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007596233,"threshold_uncertainty_score":0.0254119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.063617209979282,"score_gpt":0.3828651709096185,"score_spread":0.3192479609303365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}